HOOKIPA Pharma Inc..
HOOK.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
HOOKIPA Pharma Inc. is a biopharmaceutical company focused on developing immunotherapies targeting infectious diseases and cancers. The company's proprietary arenavirus platform is designed to reprogram the body's immune system to fight disease. Their pipeline includes novel immunotherapies for vari...Show More
Better Health for All
-10
HOOKIPA Pharma's core business is developing immunotherapies for serious diseases like cancer, HIV, and Hepatitis B, aiming for functional cures, which represents an exceptional health benefit.
1
The company has no revenue from products with negative health outcomes.
2
Clinical trial data for HB-200 showed 11.8% of patients experienced grade ≥3 treatment-related adverse events and 2.2% discontinued due to these events.
3
The company's HB-500 program targets HIV, which affects over 38 million people worldwide, and HB-700 targets KRAS-mutated cancers, including lung, colorectal, and pancreatic cancers.
4
The company discloses risks associated with product development, regulatory approvals, manufacturing, competition, and financial position in its SEC filings.
5
HOOKIPA has received significant investments for its programs, including a $25 million upfront payment and potential milestones up to $930 million from Roche, and a $21.25 million equity investment from Gilead for the HIV program, with development milestones up to $172.5 million for HIV and $140 million for HBV.
6
The company states it complies with applicable data privacy laws and has complied with Privacy Laws since January 1, 2022.
7
HOOKIPA is developing therapies for HIV and HBV, which are major global health challenges.
8
The company's focus is on therapeutic vaccines and treatments, rather than preventative measures.
9
Clinical trials for HB-500, HB-400, and HB-200 are ongoing, with the company stating compliance with cGCPs, cGLPs, and cGMPs since January 1, 2022, and receiving FDA clearance for IND applications.
10
Fair Money & Economic Opportunity
0
HOOKIPA Pharma Inc. is a biopharmaceutical company focused on developing immunotherapies. Its core business does not involve providing financial services to consumers, such as lending, insurance, or money management. Therefore, the company does not offer consumer credit products, manage customer finance data, or operate financial service access points. The evidence provided does not contain information relevant to the company's engagement in financial services or its impact on economic opportunity for underserved populations. The rubric's '0' tier for each KPI is applicable as the company's business model falls outside the scope of financial services.
Fair Pay & Worker Respect
0
No evidence available to assess HOOKIPA Pharma Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess HOOKIPA Pharma Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
HOOKIPA Pharma Inc. received an Accountable Institutions Score of 34.3 from Ethos ESG.
1
The company has a Code of Business Conduct and Ethics, adopted in January 2019, which includes a whistle-blower policy.
2
This policy provides multiple anonymous reporting channels, such as an online platform and a voicemail number, and explicitly forbids retaliation against employees who report suspected misconduct in good faith.
3
All directors, officers, and employees are supplied with the Code and are expected to review and sign an acknowledgment periodically.
4
The company has not had any financial restatements that required a recovery analysis of incentive-based compensation, as indicated by unchecked boxes on its Form 10-K/A filed in April 2025.
5
The Board of Directors has determined that 75% of its directors are independent, with three directors identified as having relationships that interfere with independent judgment.
6
The company's Code of Business Conduct and Ethics includes an anti-corruption policy that prohibits bribes, kickbacks, and other improper payments, applying to all directors, officers, and employees.
7
A current copy of this Code is posted on the company's website.
8
Kind to Animals
0
The company utilizes animal testing in its research and development, specifically demonstrating its HB-700 product in several different animal and translational models.
1
However, no specific details regarding the volume of animals used, the company's animal testing policy, or any investment in animal-free alternatives are available in the provided articles.
2
No War, No Weapons
0
The provided articles for HOOKIPA Pharma Inc. (HOOK.US) focus on the company's biopharmaceutical activities, including internal restructuring, strategic priorities, and clinical trial updates for oncology and infectious disease programs.
1
No information was found regarding the company's involvement in defense contracts, arms sales, dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, or any other metrics relevant to the 'No War, No Weapons' value.
2
Therefore, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
-20
In 2023, the company's total Scope 1, 2, and 3 greenhouse gas emissions were 1,235 metric tons CO2e.
1
The company has a target to reduce these emissions by 22% by 2026.
2
It also aims to reduce total energy consumption from 247,350 kWh in 2023 to a target of 210,247 kWh in 2024, and manufacturing waste from 18.6 metric tons in 2023 to a target of 14.3 metric tons by 2025.
3
Respect for Cultures & Communities
0
No specific quantitative data or relevant information regarding HOOK.US's performance on 'Respect for Cultures & Communities' was provided in the article.
1
Safe & Smart Tech
0
No evidence available to assess HOOKIPA Pharma Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-20
HOOKIPA Pharma Inc. has established quantitative waste reduction targets with specific timelines. The company aims for an 18% overall waste reduction by 2024.
1
Additionally, it targets a reduction in manufacturing waste from 18.6 metric tons in 2023 to 14.3 metric tons by 2025, which represents an approximate 23.12% reduction for that specific waste stream.
2